Acura says that a generic of Acura's AVERSION oxycodone product, previously marketed by Pfizer Inc in the suit, under its brand name OXECTA
, for which Ranbaxy is looking for approval to market in the United States pursuant to an Abbreviated New Drug Application (ANDA) filing with the U.
Following the immediate cancellation of the letter license agreement, Pfizer's returns its FDA approved Oxecta
(oxycodone HCl) product to Acura Pharmaceuticals.
is the first approved and marketed product utilizing Acura's proprietary Aversion technology.
M2 EQUITYBITES-July 2, 2013-Acura announces commercial expansion of OXECTA
by Pfizer in US(C)2013 M2 COMMUNICATIONS http://www.
M2 PHARMA-July 2, 2013-Acura announces commercial expansion of OXECTA
by Pfizer in US(C)2013 M2 COMMUNICATIONS
In June 2011, the US Food and Drug Administration (FDA) approved Lazanda (fentanyl nasal spray; Archimedes) for the management of breakthrough pain in cancer patients and Oxecta
(oxycodone hydrochloride; Acura Pharmaceuticals/Pfizer) for acute and chronic moderate to severe pain.
In addition, the company has licensed certain claims in this patent to Pfizer Inc (NYSE: PFE) which utilises the former's AVERSION technology in its Oxecta
(oxycodone HCl) tablets CII.
is covered and issued to Acura and licensed to Pfizer.
Pfizer is licensing the technology in OXECTA
Speciality pharmaceutical company Acura Pharmaceuticals Inc (NASDAQ:ACUR) reported on Thursday that it has received notification from a generic sponsor of the filing of an Abbreviated New Drug Application (ANDA) for a generic drug listing OXECTA
(oxycodone HCl) Tablets CII as the reference listed drug.
However, Acura's fourth product with its AVERSION Technology, OXECTA
(oxycodone hydrochloride) Tablets CII, is being commercialised by Pfizer, who will retain all rights and obligations to OXECTA
M2 PHARMA-January 24, 2012-Acura announces commercial availability of OXECTA
(oxycodone HCl, USP) Tablets CII(C)2012 M2 COMMUNICATIONS